OncologyUpdated Results from a Prospective Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with bevacizumab By Graviton / 06/2019 ASCO
OncologyFASN inhibition as a potential treatment for therapy of endocrine resistant breast cancer By natalia / 12/2018 San Antonio Breast Cancer Symposium
NASHFibroblast Growth Factor-21 and its Relationship to Human Liver Fat Synthesis; Impact of a New Therapeutic Agent By Graviton / 11/2018 ObesityWeek
OncologyUpdated results from a prospective, randomized phase 2 study in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with Avastin versus Avastin alone By natalia / 11/2018 Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
NASHProgressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN By Graviton / 01/2018 Keystone Symposium on Organ Crosstalk in Obesity and NAFLD
OncologyFatty acid synthase inhibitor TVB-3664 reverses multiple components of diet-induced nonalcoholic steatohepatitis in mice treated with or without co-administered pirfenidone and reduces collagen accumulation in bleomycin-induced murine skin fibrosis By Graviton / 10/2017 AASLD
NASHPharmacologic Inhibition of FASN Reverses Diet-Induced Steatohepatitis in Mice and Inhibits Lipogenesis in Humans. By Graviton / 10/2017 AASLD
OncologyFirst in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640 By Graviton / 04/2017 AACR Annual Meeting